Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Composition vs Utility Patent Question
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Post by TheBearInTheWoodson Sep 11, 2020 6:30pm
145 Views
Post# 31547196

Composition vs Utility Patent Question

Composition vs Utility Patent QuestionScenerio #1

Since 1970 ACME Clothes Hanger inc has been making clothes hangers under a composition patent, the patent is for hanging clothes from a wire made hanger. This product has been trusted for years due to reliabilty.

BREAKING NEWS!!!! March 2020 during a keys locked in truck Crisis 

Big Als Clothes Hanger has put in a Utility Patent to Bend said wire hanger and unlock a 1998 Chevy truck!!!!! They are "developing the fast use, just bend here product" 

Ask yourself, would you buy the ACME or Big als product if you locked your keys in BIG ALs truck. You can use one product for anything, or you can use one product only if you own the chevy.

If you say Big Als, then do I have the Company for you!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities